{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:43:47Z","timestamp":1793853827275,"version":"4.6.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010040","name":"Taishan Scholar Project of Shandong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019446","name":"Medical and Health Science and Technology Development Project of Shandong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019446","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jaad.2025.05.1374","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T11:40:01Z","timestamp":1747136401000},"page":"634-643","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Efficacy, safety, and B-cell depletion capacity of 3 rituximab dosing regimens in the treatment of moderate-to-severe pemphigus vulgaris and pemphigus foliaceus: A 52-week clinical trial"],"prefix":"10.1016","volume":"93","author":[{"given":"Shan","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoqi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoxia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Futang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanqing","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jaad.2025.05.1374_bib1","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/bjd\/ljae220","article-title":"The emergence of circulating activated autoreactive Dsg3-specific Tfr cells is associated with long-term efficacy of RTX in PV patients","volume":"191","author":"H\u00e9bert","year":"2024","journal-title":"Br J Dermatol"},{"issue":"10201","key":"10.1016\/j.jaad.2025.05.1374_bib2","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0140-6736(19)31778-7","article-title":"Pemphigus","volume":"394","author":"Schmidt","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jaad.2025.05.1374_bib3","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1111\/1346-8138.16145","article-title":"Sustainable effect of ultra-low dose rituximab for mild-to-moderate pemphigus vulgaris: a case report","volume":"48","author":"Wang","year":"2021","journal-title":"J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.05.1374_bib4","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/jid.2011.249","article-title":"Incidence, mortality, and causes of death of patients with pemphigus in Taiwan: a nationwide population-based study","volume":"132","author":"Huang","year":"2012","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.05.1374_bib5","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jid.2018.07.042","article-title":"Incidence and mortality of pemphigus in France","volume":"139","author":"Jelti","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2025.05.1374_bib6","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1365-4632.2004.02533.x","article-title":"Pemphigus in the Mediterranean region of Turkey: a study of 148 cases","volume":"45","author":"Uzun","year":"2006","journal-title":"Int J Dermatol"},{"issue":"10083","key":"10.1016\/j.jaad.2025.05.1374_bib7","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.jaad.2025.05.1374_bib8","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa2028564","article-title":"Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris","volume":"384","author":"Werth","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jaad.2025.05.1374_bib9","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/1096-8652(200102)66:2<142::AID-AJH1032>3.0.CO;2-0","article-title":"Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL","volume":"66","author":"Heizmann","year":"2001","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.jaad.2025.05.1374_bib10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/rheumatology\/40.2.205","article-title":"Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes","volume":"40","author":"Edwards","year":"2001","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.jaad.2025.05.1374_bib11","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/ard.61.10.883","article-title":"Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion","volume":"61","author":"Leandro","year":"2002","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.jaad.2025.05.1374_bib12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4103\/ijdvl.IJDVL_1078_14","article-title":"Low-dose rituximab as an adjuvant therapy in pemphigus","volume":"83","author":"Gupta","year":"2017","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"2","key":"10.1016\/j.jaad.2025.05.1374_bib13","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2133.2011.10663.x","article-title":"Low-dose rituximab is effective in pemphigus","volume":"166","author":"Horv\u00e1th","year":"2012","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.05.1374_bib14","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/bjd.20819","article-title":"Ultralow-dose rituximab in pemphigus: a single-centre experience","volume":"186","author":"Simpson","year":"2022","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.05.1374_bib15","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/14712598.2020.1727440","article-title":"Ultra-low dose rituximab for refractory pemghigus vulgaris: a pilot study","volume":"20","author":"Russo","year":"2020","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"10.1016\/j.jaad.2025.05.1374_bib16","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jaad.2024.07.1506","article-title":"A study of ultralow dose rituximab as adjuvant to standard of care in treatment of significant and extensive pemphigus vulgaris: a case series","volume":"91","author":"Patel","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2025.05.1374_bib17","doi-asserted-by":"crossref","first-page":"e587","DOI":"10.1111\/jdv.19760","article-title":"Ultra-low-dose rituximab: alternative treatment for autoimmune dermatological conditions","volume":"38","author":"Reyes-Soto","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2025.05.1374_bib18","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41598-017-17934-6","article-title":"Single, very low rituximab doses in healthy volunteers - a pilot and a randomized trial: implications for dosing and biosimilarity testing","volume":"8","author":"Schoergenhofer","year":"2018","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.jaad.2025.05.1374_bib19","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/jdv.16752","article-title":"Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)","volume":"34","author":"Joly","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.jaad.2025.05.1374_bib20","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.05.1374_bib21","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/bjd.14405","article-title":"Calculation of cut-off values based on the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus","volume":"175","author":"Boulard","year":"2016","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2025.05.1374_bib22","first-page":"516","article-title":"S2k guidelines for the treatment of pemphigus vulgaris\/foliaceus and bullous pemphigoid: 2019 update","volume":"18","author":"Schmidt","year":"2020","journal-title":"J Dtsch Dermatol Ges"},{"issue":"6","key":"10.1016\/j.jaad.2025.05.1374_bib23","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa067752","article-title":"A single cycle of rituximab for the treatment of severe pemphigus","volume":"357","author":"Joly","year":"2007","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jaad.2025.05.1374_bib24","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/bjd.12972","article-title":"Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded study","volume":"170","author":"Kanwar","year":"2014","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.05.1374_bib25","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jaad.2022.06.1187","article-title":"Clinical observation of different doses of rituximab for the treatment of severe pemphigus: a single-center prospective cohort study","volume":"88","author":"Zhang","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.05.1374_bib26","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2024.2302071","article-title":"The efficacy and safety of low-dose rituximab in the treatment of pemphigus vulgaris: a cohort study","volume":"35","author":"Zhou","year":"2024","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"10.1016\/j.jaad.2025.05.1374_bib27","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jaad.2010.07.032","article-title":"Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients","volume":"65","author":"Kasperkiewicz","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"175","key":"10.1016\/j.jaad.2025.05.1374_bib28","doi-asserted-by":"crossref","first-page":"175ra30","DOI":"10.1126\/scitranslmed.3005166","article-title":"Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response","volume":"5","author":"Colliou","year":"2013","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.jaad.2025.05.1374_bib29","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/j.1365-2133.2011.10411.x","article-title":"Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients","volume":"165","author":"Kim","year":"2011","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2025.05.1374_bib30","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1111\/1346-8138.17505","article-title":"Pemphigus relapse: mechanisms, risk factors, and agents associated with disease recurrence","volume":"51","author":"Pathak","year":"2024","journal-title":"J Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2025.05.1374_bib31","doi-asserted-by":"crossref","first-page":"928","DOI":"10.2340\/00015555-2116","article-title":"Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens","volume":"95","author":"Wang","year":"2015","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"10.1016\/j.jaad.2025.05.1374_bib32","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/jamadermatol.2020.0290","article-title":"Factors associated with short-term relapse in patients with pemphigus who receive rituximab as first-line therapy: a post hoc analysis of a randomized clinical trial","volume":"156","author":"Mignard","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2025.05.1374_bib33","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3389\/fimmu.2018.00248","article-title":"Effectiveness and safety of rituximab in recalcitrant pemphigoid diseases","volume":"9","author":"Lamberts","year":"2018","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.jaad.2025.05.1374_bib34","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jaad.2011.11.007","article-title":"Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up","volume":"67","author":"Cianchini","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.05.1374_bib35","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00415-020-10362-z","article-title":"Rituximab for the treatment of multiple sclerosis: a review","volume":"269","author":"Chisari","year":"2022","journal-title":"J Neurol"},{"issue":"8","key":"10.1016\/j.jaad.2025.05.1374_bib36","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1111\/ced.15213","article-title":"Comparison of the efficacy and cost-effectiveness of an immunologically targeted low-dose rituximab protocol with the conventional rheumatoid arthritis protocol in severe pemphigus","volume":"47","author":"Singh","year":"2022","journal-title":"Clin Exp Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225021127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225021127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T13:13:25Z","timestamp":1762262005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225021127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0190962225021127"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.05.1374","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy, safety, and B-cell depletion capacity of 3 rituximab dosing regimens in the treatment of moderate-to-severe pemphigus vulgaris and pemphigus foliaceus: A 52-week clinical trial","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.05.1374","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}